MAB3564
抗钠/碘同向转运体，a.a.625-643，克隆FP5A
clone FP5A, Chemicon®, from mouse
别名:
Na+/I- Symporter, NIS
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
FP5A, monoclonal
Application:
IHC (p), WB
Citations:
7
biological source
mouse
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
FP5A, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable, western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... SLC5A5(6528)
Immunogen
与人NIS（C端）氨基酸468-643相对应的麦芽糖结合蛋白融合蛋白。
表位：氨基酸625-643
Application
使用该抗钠/碘同向转运体检测钠/碘同向转运体，a.a.625-643，克隆经验证的FP5A，以应用于IH、IH(P) & WB。
免疫印迹。该抗体可识别分子量约为97 kDa的主带以及15 kDa、30 kDa、68 kDa和160 kDa的小带。
免疫组化。该抗体对石蜡包埋组织切片有效，这些切片使用10mM柠檬酸盐缓冲蒸汽提取抗原30分钟。
最佳工作稀释度必须由最终用户进行确定。
免疫组化。该抗体对石蜡包埋组织切片有效，这些切片使用10mM柠檬酸盐缓冲蒸汽提取抗原30分钟。
最佳工作稀释度必须由最终用户进行确定。
Biochem/physiol Actions
钠/碘同向转运体（NIS）。该表位被认为位于人类NIS的625-643氨基酸区域。该抗体可能对麦芽糖结合蛋白有一定反应性。
Physical form
形式：纯化
Other Notes
浓度：请参考批次特异性浓缩物的检验报告。
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Annie Yang et al.
Journal for immunotherapy of cancer, 11(4) (2023-04-06)
Gastric cancer (GC) that metastasizes to the peritoneum is fatal. CF33 and its genetically modified derivatives show cancer selectivity and oncolytic potency against various solid tumors. CF33-hNIS and CF33-hNIS-antiPDL1 have entered phase I trials for intratumoral and intravenous treatments of
Christina Schug et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(19), 5997-6008 (2019-06-15)
The innate tumor homing potential of mesenchymal stem cells (MSCs) has been used for a targeted delivery of the theranostic sodium iodide symporter (NIS) transgene into solid tumors. We have previously shown that external beam radiotherapy (EBRT) results in the
Carolin Kitzberger et al.
Molecular therapy oncolytics, 30, 238-253 (2023-09-13)
New treatment strategies are urgently needed for glioblastoma (GBM)-a tumor resistant to standard-of-care treatment with a high risk of recurrence and extremely poor prognosis. Based on their intrinsic tumor tropism, adoptively applied mesenchymal stem cells (MSCs) can be harnessed to
Rebekka Spellerberg et al.
Molecular therapy oncolytics, 27, 272-287 (2022-12-03)
Sodium iodide symporter (NIS) gene transfer for active accumulation of iodide in tumor cells is a powerful theranostic strategy facilitating both diagnostic and therapeutic application of radioiodide. In glioblastoma (GBM), the blood-brain barrier (BBB) presents an additional delivery barrier for
Danielle L Gainor et al.
JAMA otolaryngology-- head & neck surgery, 141(8), 739-744 (2015-06-05)
Sodium iodide symporter (NIS) expression in adenoid cystic carcinoma (ACC) has not been fully elucidated in the literature, and it is unclear whether radioactive iodine may be a potential therapeutic modality. To our knowledge, the present study includes the largest
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持